Scisparc Ltd Total Assets
Scisparc Ltd total assets. Based on the latest financial reports, Scisparc Ltd (SPRC) holds total assets worth $7.62 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Scisparc Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Scisparc Ltd (2006–2025)
Total assets of Scisparc Ltd from 2006 to 2025. This chart illustrates how Scisparc Ltd's total assets have evolved over time, based on quarterly financial data. See Scisparc Ltd share price for real-time trading data and today's change.
Scisparc Ltd - Asset Composition Analysis
Scisparc Ltd Total Assets Breakdown (December 2025)
Scisparc Ltd total assets breakdown as of December 2025. Scisparc Ltd's total assets of $7.62 Million consist of 71.3% current assets and 28.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.2% |
| Accounts Receivable | $662.00K | 8.7% |
| Inventory | $75.00K | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.17 Million | 15.4% |
Asset Composition Trend (2006–2025)
This chart illustrates how Scisparc Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SPRC working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Scisparc Ltd's current assets represent 71.3% of total assets in 2025, a decrease from 98.3% in 2006.
- Cash Position: Cash and equivalents constituted 60.2% of total assets in 2025, up from 50.6% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is goodwill at 15.4% of total assets.
Scisparc Ltd Competitors by Total Assets
Key competitors of Scisparc Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Scisparc Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 5.36 | 11.05 |
| Quick Ratio | 2.38 | 5.28 | 11.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.18 Million | $6.10 Million | $7.58 Million |
Scisparc Ltd - Advanced Valuation Insights
This section examines the relationship between Scisparc Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.71 |
| Latest Market Cap to Assets Ratio | 2.05 |
| Asset Growth Rate (YoY) | -26.3% |
| Total Assets | $7.62 Million |
| Market Capitalization | $15.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Scisparc Ltd's assets at a significant premium (2.05x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Scisparc Ltd's assets decreased by 26.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Scisparc Ltd (2006–2025)
The table below shows the annual total assets of Scisparc Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.62 Million | -26.34% |
| 2024-12-31 | $10.35 Million | -7.47% |
| 2023-12-31 | $11.18 Million | +5.44% |
| 2022-12-31 | $10.61 Million | +6.95% |
| 2021-12-31 | $9.92 Million | +287.19% |
| 2020-12-31 | $2.56 Million | +121.92% |
| 2019-12-31 | $1.15 Million | -74.69% |
| 2018-12-31 | $4.56 Million | -52.33% |
| 2017-12-31 | $9.57 Million | +668.52% |
| 2016-12-31 | $1.24 Million | -25.26% |
| 2015-12-31 | $1.67 Million | +537.64% |
| 2014-12-31 | $261.18K | -84.56% |
| 2013-12-31 | $1.69 Million | +54.83% |
| 2012-12-31 | $1.09 Million | -75.33% |
| 2011-12-31 | $4.43 Million | -55.63% |
| 2010-12-31 | $9.98 Million | -18.32% |
| 2009-12-31 | $12.22 Million | +22.00% |
| 2008-12-31 | $10.01 Million | -34.18% |
| 2007-12-31 | $15.22 Million | +35.65% |
| 2006-12-31 | $11.22 Million | -- |
About Scisparc Ltd
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil… Read more